These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26967126)

  • 41. Individualizing tapering antipsychotic schemes considering D2 blockade dynamics.
    Costardi CG; Gadelha A; Bressan RA
    J Psychopharmacol; 2021 Sep; 35(9):1161-1162. PubMed ID: 34313143
    [No Abstract]   [Full Text] [Related]  

  • 42. Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials.
    Zheng W; Li XB; Shi ZM; Yang XH; Cai DB; Ng CH; Ungvari GS; Liu WJ; Wu YJ; Wang YY; Ning YP; Xiang YT
    Pharmacopsychiatry; 2020 Jan; 53(1):5-13. PubMed ID: 31207653
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
    Grunder G; Carlsson A; Wong DF
    Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.
    Mallet J; Gorwood P; Le Strat Y; Dubertret C
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):651-664. PubMed ID: 31406978
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis.
    Zheng W; Xiang YQ; Li XB; Ungvari GS; Chiu HF; Sun F; D'Arcy C; Meng X; Xiang YT
    Hum Psychopharmacol; 2016 Jul; 31(4):286-95. PubMed ID: 27302211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Oya K; Kishi T; Iwata N
    Neuropsychiatr Dis Treat; 2015; 11():2299-307. PubMed ID: 26366084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis.
    Brandt L; Schneider-Thoma J; Siafis S; Efthimiou O; Bermpohl F; Loncar L; Neumann K; Hasan A; Heinz A; Leucht S; Gutwinski S
    Lancet Psychiatry; 2022 Mar; 9(3):232-242. PubMed ID: 35183280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data.
    Lochmann van Bennekom MWH; IntHout J; Gijsman HJ; Akdede BBK; Yağcıoğlu AEA; Barnes TRE; Galling B; Gueorguieva R; Kasper S; Kreinin A; Nielsen J; Nielsen RE; Remington G; Repo-Tiihonen E; Schmidt-Kraepelin C; Shafti SS; Xiao L; Correll CU; Verkes RJ
    Schizophr Res; 2024 Oct; 272():1-11. PubMed ID: 39142215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can Aripiprazole Worsen Psychosis in Schizophrenia? A Meta-Analysis of Double-Blind, Randomized, Controlled Trials.
    Takeuchi H; Fathi A; Thiyanavadivel S; Agid O; Remington G
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29570965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.
    Sakuma K; Matsunaga S; Nomura I; Okuya M; Kishi T; Iwata N
    Psychopharmacology (Berl); 2018 Aug; 235(8):2303-2314. PubMed ID: 29785555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
    Kishi T; Matsuda Y; Iwata N
    Psychopharmacology (Berl); 2017 Jul; 234(14):2113-2125. PubMed ID: 28508107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A safety evaluation of aripiprazole in the treatment of schizophrenia.
    Preda A; Shapiro BB
    Expert Opin Drug Saf; 2020 Dec; 19(12):1529-1538. PubMed ID: 33064050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rapid vs. slow antipsychotic initiation in schizophrenia: A systematic review and meta-analysis.
    Takeuchi H; Thiyanavadivel S; Agid O; Remington G
    Schizophr Res; 2018 Mar; 193():29-36. PubMed ID: 28844639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis.
    Matsui K; Tokumasu T; Takekita Y; Inada K; Kanazawa T; Kishimoto T; Takasu S; Tani H; Tarutani S; Hashimoto N; Yamada H; Yamanouchi Y; Takeuchi H
    Schizophr Res; 2019 Jul; 209():50-57. PubMed ID: 31182319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.
    Alfageh BH; Wang Z; Mongkhon P; Besag FMC; Alhawassi TM; Brauer R; Wong ICK
    Paediatr Drugs; 2019 Jun; 21(3):153-167. PubMed ID: 31134563
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis.
    Vayısoğlu S; Karahan S; Anıl Yağcıoğlu AE
    Turk Psikiyatri Derg; 2019; 30(4):253-259. PubMed ID: 32594486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
    Lähteenvuo M; Tiihonen J
    Drugs; 2021 Jul; 81(11):1273-1284. PubMed ID: 34196945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials.
    Oya K; Matsuda Y; Matsunaga S; Kishi T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2016 Aug; 266(5):439-50. PubMed ID: 26303414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Jiang WL; Cai DB; Yin F; Zhang L; Zhao XW; He J; Ng CH; Ungvari GS; Sim K; Hu ML; Zheng W; Xiang YT
    Transl Psychiatry; 2020 Apr; 10(1):117. PubMed ID: 32327628
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.
    Galling B; Roldán A; Nielsen RE; Nielsen J; Gerhard T; Carbon M; Stubbs B; Vancampfort D; De Hert M; Olfson M; Kahl KG; Martin A; Guo JJ; Lane HY; Sung FC; Liao CH; Arango C; Correll CU
    JAMA Psychiatry; 2016 Mar; 73(3):247-59. PubMed ID: 26792761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.